Abstract
Rifampicin is an established and effective antibiotic and is the gold standard in the treatment of tuberculosis (TB). Its use is reserved for serious bacterial infections, such as active and latent leprosy. Tuberculosis is the most prevalent infectious disease worldwide as well as in India. Therefore, despite recent progress tuberculosis remains an important global public health problem. According to WHO, TB statistic 2020, the global incidence of TB was 15.6 million and in India, it was 5.6 million. In India, most of the antituberculosis regimens under the Revised National Tuberculosis Control Programme (RNTCP) are rifampicin-based. Deep Vein Thrombosis events are a rare side effect of rifampicin, which has been reported in a few parts of the world. Here we report a case of a male patient with pulmonary tuberculosis initiated on ATT drug regimen presented with deep vein thrombosis due to rifampicin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pharmaceutical Sciences Review and Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
